Research programme: AMPK activators - Antisoma/Betagenon
Latest Information Update: 15 Jun 2011
At a glance
- Originator Betagenon
- Developer Antisoma; Betagenon
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Apr 2008 Preclinical trials in Cancer in United Kingdom (unspecified route)